Tag Archives: Keryx

Disappointing Results for Perifosine

Perifosine was no better than a placebo in improving survival time for people with late-stage colorectal cancer according to a news release from Keryx Biopharmaceuticals. Despite success in a smaller Phase II clinical trial, the X-PECT Phase III trial failed to meet its primary objective — longer survival time. X-PECT randomized 468 patients to receive either: Xeloda® (capecitabine) plus perifosine, or Xeloda plus a placebo Although final details were not provided, the perifosine group did not live longer than the patients who got a dummy pill. Patients in the trial had refractory colorectal cancer, tumors that had already gotten worse on at least two standard chemotherapy regimens. Had perifosine helped

Top